Genmab — Januar 2024
-
Jo fase 3 forsøgene er jo en nødvendighed, særligt nu da voldgiften er tabt og burde blive belønnet som et fremskridt. Gmab skal jo bare huske at highlighte deres succesrate. Så bliver det jo så godt som money in the bank
Men guidance skal helst bekræfte den fortsat kraftige vækst -
from
Scancell Interim Results for the six months ended 31 October 2023- Antibodies:
• Development of SC129, out licensed to Genmab, continues on track towards potential clinical
development.
https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/2024/scancell-interim-results-31-october-2023.pdf -
Novel Cervical Cancer Treatments in Clinical Trial https://news.med.miami.edu/novel-cervical-cancer-treatments-in-clinical-trial/ “The antibody drug conjugate tisotumab vedotin-tftv has also gained approval and became a standard-of-care therapy this year. This therapy extends survival significantly,” said Dr. Sinno.
-
-
Pfizer skriver at FDA har accepteret Tivdak sBLA ansøgning om konvertering fra "accelerated approval" til fuld godkendelse med priority review og PDUFA dato d. 9 maj, se link side 8. 2024.https://s28.q4cdn.com/781576035/files/doc_financials/2023/q4/Q4-2023-PFE-Earnings-Release.pdf
-
Svar fra Andrew Carlsen angående stilleperioden "Our quiet period before earnings is still 2 weeks and has not been extended to 4 weeks with the US listing."
-
You are welcome.
-
Egentlig en meget subtil måde at spørge “hvad f#€&”€en i h#€”&€&€lvede foregår der!?”
-
The third Pfizer product to hit the reject pile is PF-07260437, a phase 1 therapy designed to treat advanced breast cancer, ovarian cancer or endometrial cancer. The B7-H4 x CD3 bispecific monoclonal antibody was being tested among 30 patients in a study that wrapped in October of last year, as listed on ClinicalTrials.gov.
-
-
This decision was not due to major safety concerns (fra Clinical Trials)https://classic.clinicaltrials.gov/ct2/show/NCT05067972
-
Godmorgen
-
Dagens regnskaber: https://www.proinvestor.com/finanskalender
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind